RxDoctor Payments Data

Anjani Kota, MD

Internal Medicine · East Setauket, NYNPI 1720055353

Payments from drug & device makers

$3,470in general payments, 2019–2025

Across 142 payments — averaging $24.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$974
  • Lilly USA, LLC$807
  • Novo Nordisk$732
  • Exact Sciences$175
  • Amarin Pharma, Inc.$171
  • Boehringer Ingelheim$158
  • plus $453 from 8 others

What the payments were for

  • Food & beverage$3,43599%
  • Education$351%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,470 in reported general payments places this provider in the 85th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$112,153
Medicare patients
182
Services billed
968

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide25$51,484
OzempicSemaglutide13$28,643
Tresiba Flextouch U-200Insulin Degludec11$14,684
JardianceEmpagliflozin22$9,710
Levothyroxine Sodium186$3,157
Nebivolol Hcl17$2,848
Rosuvastatin Calcium168$2,476
Metoprolol Succinate105$1,890
Atorvastatin Calcium101$1,487
Amlodipine Besylate162$1,288
Omega-3 Acid Ethyl Esters11$1,286
Ezetimibe32$1,101
Fluticasone Propionate29$925
SynthroidLevothyroxine Sodium24$891
Enalapril Maleate54$867

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity$807$51,48425 claims
Novo NordiskOzempic$732$28,64313 claims
Boehringer IngelheimJardiance$158$9,71022 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in East Setauket

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →